S
Sumeng Wang
Researcher at Nanjing Medical University
Publications - 5
Citations - 164
Sumeng Wang is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Cancer & Liquid biopsy. The author has an hindex of 2, co-authored 5 publications receiving 31 citations.
Papers
More filters
Journal ArticleDOI
Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies
Sumeng Wang,Ke Zhang,Shanyue Tan,Junyi Xin,Qianyu Yuan,Huanhuan Xu,Xian Xu,Qi Liang,David C. Christiani,Meilin Wang,Lingxiang Liu,Mulong Du +11 more
TL;DR: Wang et al. as discussed by the authors summarized the expression of circRNAs in body fluids in a pan-cancer dataset and characterized their clinical applications in liquid biopsy for cancer diagnosis and prognosis.
Journal ArticleDOI
Acupuncture for Cancer Pain - An Adjuvant Therapy for Cancer Pain Relief.
TL;DR: This work preliminarily summarized frequently-used acupoints for different types of cancer pain and found that needle retention time was mostly 30 min, and treatment cycle was two weeks, and Interestingly, acupuncture can treat both tumor- induced pain and therapy-induced pain well among cancer patients.
Journal ArticleDOI
A methylation-based prognostic model predicts survival in patients with colorectal cancer.
TL;DR: In this article, a model that could effectively predict the prognosis of colorectal cancer (CRC) by searching for methylated-differentially expressed genes (MDEGs) was proposed.
Journal ArticleDOI
Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Qi Liang,Huanhuan Xu,Yiqian Liu,Weiming Zhang,Chongqi Sun,Meng Hu,Yizhi Zhu,Shanyue Tan,Xian Xu,Sumeng Wang,Lingxiang Liu +10 more
TL;DR: In this article, the authors reported that the coexistence of a novel Neurobeachin (NBEA)-ALK, Echinoderm microtubule-associated protein-like 4 gene (EML4) and anaplastic lymphoma kinase gene (ALK) fusion is the most common ALK rearrangements in non-small cell lung cancer (NSCLC).
Journal ArticleDOI
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
TL;DR: In this paper, a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr was presented.